ZEISS Expands Cataract Workflow with New CT LUCIA 621P Launch in Japan

ZEISS Expands Its Cataract Workflow in Japan with the CT LUCIA 621P

In a significant leap forward for optical healthcare, ZEISS Medical Technology has introduced the CT LUCIA® 621P monofocal intraocular lens (IOL) to the Japanese market. This launch aims to enhance the ZEISS Cataract Workflow, designed specifically to improve the visual outcomes of patients undergoing cataract surgery. This news is set to be showcased at the 80th Annual Congress of Japan Clinical Ophthalmology (JCO) to be held in Kyoto from October 29 to November 1, 2026.

Andreas Völker, the Head of the Ophthalmology Strategic Business Unit at ZEISS Medical Technology, expressed enthusiasm about this development, emphasizing the impact it will have on the future of ophthalmology in Japan. He stated, "By introducing meaningful innovations to ophthalmologists, we aim to provide them with greater options, ultimately improving patient care and outcomes. Our continued global expansion places both ophthalmologists and their patients at the forefront of our initiatives."

Vincent Mathieu, CEO of ZEISS Group Japan, also shared insights regarding the significance of the CT LUCIA 621P launch. He remarked, "This launch signifies an important expansion of our ZEISS Cataract Workflow, catering to the needs of ophthalmic surgeons and their patients across Japan. We have actively listened to the demands of professionals in the field and are excited to widen our product range with this innovative lens."

The CT LUCIA 621P IOL integrates an advanced ZEISS Optic (ZO) Asphericity Concept that tackles the inherent misalignment between the optical axis of the eye and the cornea's center. This feature contributes to reliable visual outcomes for a broad spectrum of patients. Furthermore, the IOL's reinforced optic-haptic junction and step-vaulted C-loop haptics design facilitates optimal positioning and stability during and after surgery, ensuring consistent performance post-implantation.

The ZEISS CT LUCIA 621P is not just an advancement in technology; it is a response to the evolving needs of patients and healthcare providers in Japan. The introduction offers a dual benefit: promoting efficiency in cataract surgeries while prioritizing patient satisfaction through improved visual results.

For further information about the ZEISS CT LUCIA 621P IOL and its official availability in Japan, stakeholders are encouraged to reach out to their respective ZEISS account representatives or visit their official website.

In conclusion, the launch of the CT LUCIA 621P not only augments the ZEISS Cataract Workflow but also reinforces ZEISS's commitment to advancing medical technology in the field of ophthalmology. As the company forges ahead in the global medical landscape, their focus remains steadfast on fostering innovation that directly enhances quality of life for patients.

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG is one of the world's preeminent medical technology firms, headquartered in Jena, Germany. The company is devoted to delivering solutions that empower healthcare professionals to significantly enhance their patients' quality of life. With a workforce of 5,730 globally and a revenue of €2,066.1 million for the fiscal year 2023/24, ZEISS continues to lead the way in merging advanced technology with practical applications in medicine. Their reach is extensive, with half of their employees situated in key markets such as the USA, Japan, Spain, and France. To learn more, visit www.zeiss.com/med.